Centinel Spine recently announced achievement of over $32 million in worldwide revenue for the third quarter of 2025, growing 42% over Q3 2024. The Company also set a global revenue record for its prodisc Cervical TDR product segment and achieved record positive EBITDA performance in Q3 2025,1 its fourth consecutive quarter with double-digit EBITDA margin.
Third Quarter 2025 Financial Highlights
- Worldwide prodisc TDR revenue of over $32 million, a 42% year-over-year (YOY) increase.
- Record worldwide prodisc Cervical revenue of nearly $20 million, a 34% YOY increase.
- Worldwide prodisc Lumbar revenue of over $12 million, up 58% YOY.
- U.S. prodisc TDR revenue of nearly $27 million, a 46% YOY increase.
- International prodisc TDR revenue of over $5 million, a 28% YOY increase.
- Record U.S. prodisc total surgeon user-base of over 940 surgeons in Q3 2025, a nearly 50% YOY increase.
1 Adjusted EBITDA is based on unaudited financials.
M
M